Johnson & Johnson (ETR: JNJ)
Germany
· Delayed Price · Currency is EUR | Market Cap | 333.92B |
| Revenue (ttm) | 78.55B |
| Net Income (ttm) | 13.15B |
| Shares Out | n/a |
| EPS (ttm) | 5.41 |
| PE Ratio | 25.39 |
| Forward PE | n/a |
| Dividend | 4.54 (3.31%) |
| Ex-Dividend Date | Nov 26, 2024 |
| Volume | 10,176 |
| Open | 138.22 |
| Previous Close | 139.12 |
| Day's Range | 137.26 - 138.94 |
| 52-Week Range | 132.78 - 154.00 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 22, 2025 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, Johnson & Johnson's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson: Dividend Legend At A Discount
JNJ is a strong defensive play with diversified revenue streams, impressive growth investments, and attractive stock valuation. Read why JNJ is a Strong Buy.
Transparency in Leadership: A Business Leader’s Double-Edged Sword
“Transparency breeds trust, and trust is the foundation of leadership.” – Unknown. Wikipedia describes a critical moment in the history of drug manufacturer Johnson & Johnson under the title “Chicago ...
Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy
The June/July, 2024 Fortune Magazine revealed 500 biggest U.S. companies by-revenue and profits. Arnold-research focused on 66 December industry-leaders using YCharts 12/13/24 data for Profits from 63...
Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients
The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a tr...
Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months f...
Johnson & Johnson says injectable Rybrevant rejected by FDA
J&J denied extension of patent on TB drug, to benefit patients
India News: New Delhi: In a move that will benefit tuberculosis patients, Indian Patent Office (IPO) has denied the US giant Johnson & Johnson's request to extend.
US FDA declines to approve injection form of J&J's lung cancer drug
The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.
J&J submits sBLA for pediatric indication for Simponi in ulcerative colitis
Johnson & Johnson seeks FDA approval for Simponi for pediatric ulcerative colitis. Read more here.
Insider trades: Kroger, Johnson & Johnson among notable names this week
Weekly summary of insider trading for December 9-13, 2024, including notable buying and selling activities by investors in companies like Unity Software,...
Johnson & Johnson sues Cigna units for alleging draining funds intended for copays: report
J&J accuses divisions of Cigna of helping drain its drug copay funds, WSJ reports
Johnson & Johnson has sued divisions of Cigna , accusing the health insurer of working with a drug-benefit middleman to drain J&J's financial-assistance funds earmarked for patients taking some of its...
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson (NYSE: JNJ) revealed 10 unusual trades. Delving into the details, we ...
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc...
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman and...
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, at the Westin St. Francis in San Fran...
Technology sees mixed signals: Semiconductors struggle while healthcare shines
📉 Semiconductor Sector The semiconductor sector faces a challenging day, with notable declines. Nvidia (NVDA) is down by 1.70% and Broadcom (AVGO) is sliding by 1.77%. These moves suggest a bearish o...
Lightning Round: AMD is cheap and should be bought here, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stock including: AMD, Constellation Energy, Rubrik, JD.com, Johnson & Johnson, and Netflix.
Tesla's China Sales Recover, Model Y Accounts for Over 60% of November Sales
Tesla, Inc’s (NASDAQ: TSLA) has reportedly shown strong sales performance in China, driven by continued demand for its Model Y and significant gains from the Model 3. In November, Tesla’s retail sale...
Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap
Elon Musk ‘s net worth is now more than the market capitalization of most of the listed companies in the U.S. and the world. What Happened: The SpaceX and Tesla Inc. (NASDAQ: TSLA) CEO’s net worth st...
Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends
"Dividend Aristocrats
Johnson & Johnson Just Paid Investors: Here’s How Much They Received
Johnson & Johnson has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and reliable stock. The post Johnson & Johnson Just Paid Investors: Here’...
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. J...
Johnson & Johnson's CARVYKTI® Shows Promising Results in Multiple Myeloma Treatment
Johnson & Johnson's CARVYKTI® Shows Promising Results in Multiple Myeloma Treatment
CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
89 percent of patients evaluable for MRD assessment were MRD negative, with the majority reaching MRD negativity in less than 2 months Results add to the overall survival (OS) benefits recently presen...